Actively Recruiting
Phase II Study of VRT106 Drug Combined with Radiotherapy for Adults with Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Led by Guangzhou Virotech Pharmaceutical Co., Ltd. · Updated on 2026-05-15
10
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the preliminary efficacy and safety of VRT106 combined with radiotherapy in adult patients who have diffuse midline glioma DMG or diffuse intrinsic pontine glioma DIPG. This Phase II study is designed to assess how this combination treatment affects patients with newly diagnosed or progressive forms of these serious brain tumors. Participants will receive VRT106 administered by injection along with radiotherapy. This single-arm, open-label study takes place at multiple centers and focuses on understanding the pharmacokinetics and biological effects of the combined treatment. The study does not include a comparison group and evaluates all participants under the same treatment plan. Throughout the study, participants will be monitored for disease control, progression-free survival, and overall survival over about two years. Assessments include safety, tolerability, and pharmacokinetic evaluations, along with brain imaging and clinical exams. The study lasts approximately two years, during which researchers will carefully track how patients respond to the treatment and collect data to inform future therapies.
CONDITIONS
Brief Title
A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
Research Team
Y
Yuanyuan Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
